| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9327468 | Gynecologic Oncology | 2005 | 6 Pages |
Abstract
These results suggest that MCJ methylation may be useful as a marker of response to chemotherapy in ovarian cancer and are consistent with previous in vitro data linking loss of MCJ expression with drug resistance.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Gordon Strathdee, J. Keith Vass, Karin A. Oien, Nadeem Siddiqui, Jorge Curto-Garcia, Robert Brown,